Guolian Securities released a research report on April 17 stating that it gave Garden Biotech (300401.SZ) a holding rating. The main reasons for the rating include: 1) the sluggish economy and rising costs dragged down performance. The Q1 report in '24 achieved remarkable results in reducing costs; 2) laying out synthetic biology projects, and continuing to advance convertible bond projects; 3) the VD3 main business still has high barriers and high growth logic. (Mainichi Keizai Shimbun)
国联证券4月17日发布研报称，给予花园生物（300401.SZ）持有评级。评级理由主要包括：1）景气低迷及费用提升拖累业绩，24年一季报降本成效显著；2）布局合成生物项目，可转债项目持续推进；3）VD3主业高壁垒、高成长逻辑仍存。（每日经济新闻）
Guolian Securities released a research report on April 17 stating that it gave Garden Biotech (300401.SZ) a holding rating. The main reasons for the rating include: 1) the sluggish economy and rising costs dragged down performance. The Q1 report in '24 ac
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated